InMode (INMD)

• Market cap: $1.21B
• 1 day: 0.00%
• 5 days: -7.02%
• 1 month: -14.33%
• 3 months: -1.61%
• 6 months: -9.40%
• Year to date: -6.25%
• 1 year: -27.53%
• 5 years: -24.54%
• 10 years: 134.17%

About: InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

Employees: 581

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1% less call options, than puts

Call options by funds: $40.8M | Put options by funds: $41.2M

7% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 44

3% less funds holding

Funds holding: 259 [Q2] → 251 (-8) [Q3]

8.69% less ownership

Funds ownership: 64.39% [Q2] → 55.71% (-8.69%) [Q3]

20% less capital invested

Capital invested by funds: $993M [Q2] → $799M (-$195M) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

44% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 106

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $25 57% upside
• Avg. target: $26 60% upside
• High target: $26 64% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Matt Miksic 70% 1-year accuracy 26 / 37 met price target	64% upside $26	Overweight Maintained	9 Jan 2025
BTIG Sam Eiber 100% 1-year accuracy 1 / 1 met price target	57% upside $25	Buy Initiated	17 Oct 2024